[Second line therapy for castration-resistant prostate cancer (CRPC)]

Area of Science:

• Oncology
• Urology
• Medical Diagnostics

Background:

• Castration-resistant prostate cancer (CRPC) is a significant cause of mortality in Germany, with approximately 12,000 deaths annually.
• Early detection via Prostate-Specific Antigen (PSA)-based diagnostics aids in identifying curable stages of prostate cancer.
• Docetaxel chemotherapy is a standard first-line treatment for CRPC, offering a modest survival benefit but often leading to docetaxel-insensitive disease within 6-9 months.

Purpose of the Study:

• To review the current landscape of systemic therapies for castration-resistant prostate cancer.
• To highlight the progression to docetaxel-insensitive disease and the need for secondary treatment options.
• To discuss emerging therapeutic agents and future directions in CRPC management.

Main Methods:

• Literature review of established and novel treatments for CRPC.
• Analysis of treatment efficacy and progression patterns.
• Exploration of molecular signaling pathways influencing treatment response.

Main Results:

• Docetaxel chemotherapy provides a 2-month overall survival advantage but is followed by disease progression in most patients within 6-9 months.
• A growing number of novel systemic therapies, including cabazitaxel, sipuleucel-T, and abiraterone, are becoming available.
• Understanding of molecular signal transduction is driving the development of targeted therapies.

Conclusions:

• Effective secondary systemic therapies are crucial for patients with docetaxel-insensitive CRPC.
• Emerging drugs offer promising alternatives and expand treatment options.
• Future research focusing on prospective clinical data will guide personalized therapy combinations and sequencing for specific patient subgroups.